Select Publications
Journal articles
2020, 'Factors Associated with Early Resumption of Condomless Anal Sex among Men Who Have Sex with Men after Rectal Chlamydia Treatment', Sexually Transmitted Diseases, 47, pp. 389 - 394, http://dx.doi.org/10.1097/olq.0000000000001166
,2020, 'Fast-tracking the end of HIV in the Asia Pacific region: domestic funding of key population-led and civil society organisations', The Lancet HIV, 7, pp. e366 - e372, http://dx.doi.org/10.1016/S2352-3018(20)30077-1
,2020, 'Key populations and power: people-centred social innovation in Asian HIV services', The Lancet HIV, 7, pp. e69 - e74, http://dx.doi.org/10.1016/S2352-3018(19)30347-9
,2020, 'Diagnosis and Management of Syphilis in Patients With HIV Co-infection', Current Treatment Options in Infectious Diseases, 12, pp. 215 - 226, http://dx.doi.org/10.1007/s40506-020-00225-6
,2019, 'Sociodemographic, lifestyle and metabolic predictors of all-cause mortality in a cohort of community-dwelling population: An 18-year follow-up of the North West Adelaide Health Study', BMJ Open, 9, http://dx.doi.org/10.1136/bmjopen-2019-030079
,2019, 'Addressing smoking among people living with HIV: a cross-sectional survey of Australian HIV health practitioners’ practices and attitudes', AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 31, pp. 436 - 442, http://dx.doi.org/10.1080/09540121.2018.1500007
,2019, 'Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia: trends and predictors, 2004–2015', Medical Journal of Australia, 210, pp. 269 - 275, http://dx.doi.org/10.5694/mja2.50006
,2019, 'Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps', HIV Medicine, 20, pp. 3 - 11, http://dx.doi.org/10.1111/hiv.12708
,2019, 'FRI-200-Spend less get more;cost effectiveness of various models of care in hepatitis C treatment', Journal of Hepatology, 70, pp. e479 - e479, http://dx.doi.org/10.1016/s0618-8278(19)30945-4
,2018, 'Smoking and HIV: What are the risks and what harm reduction strategies do we have at our disposal?', AIDS Research and Therapy, 15, http://dx.doi.org/10.1186/s12981-018-0213-z
,2018, 'Real-world outcomes of unrestricted direct-acting antiviral treatment for hepatitis C in Australia: The South Australian statewide experience', Journal of Viral Hepatitis, 25, pp. 1287 - 1297, http://dx.doi.org/10.1111/jvh.12943
,2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018', Journal of Virus Eradication, 4, pp. 143 - 159, http://dx.doi.org/10.1016/s2055-6640(20)30260-0
,2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', J Virus Erad, 4, pp. 143 - 159, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892678/
,2018, 'Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis', Clinical Infectious Diseases, 66, pp. 1846 - 1857, http://dx.doi.org/10.1093/cid/cix1108
,2018, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines. Update April 2018.', Journal of Virus Eradication, 4, pp. 143 - 159
,2018, 'Combination ART: are two drugs as good as three?', The Lancet, 391, pp. 817 - 819, http://dx.doi.org/10.1016/S0140-6736(18)30008-4
,2018, 'Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy', AIDS, 32, pp. 357 - 361, http://dx.doi.org/10.1097/QAD.0000000000001688
,2018, 'Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial', Antiviral Therapy, 23, pp. 21 - 32, http://dx.doi.org/10.3851/IMP3171
,2018, 'Towards a universal second-line fixed-dose combination ART', The Lancet HIV, 5, pp. e3 - e5, http://dx.doi.org/10.1016/S2352-3018(17)30180-7
,2018, 'Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia', Journal of Hepatology, 68, pp. S265 - S265, http://dx.doi.org/10.1016/s0168-8278(18)30743-8
,2017, 'Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study', PLoS Medicine, 14, pp. e1002424, http://dx.doi.org/10.1371/journal.pmed.1002424
,2017, 'The impact of changes in HIV management guidelines on time to treatment initiation in Australia', HIV Medicine, 18, pp. 701 - 703, http://dx.doi.org/10.1111/hiv.12504
,2017, 'Long-acting injectable ART: next revolution in HIV?', The Lancet, 390, pp. 1468 - 1470, http://dx.doi.org/10.1016/S0140-6736(17)31962-1
,2017, 'The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.', BMC Medicine, 15, pp. 145, http://dx.doi.org/10.1186/s12916-017-0888-3
,2017, 'Vaporised nicotine and tobacco harm reduction for addressing smoking among people living with HIV: A cross-sectional survey of Australian HIV health practitioners’ attitudes', Drug and Alcohol Dependence, 177, pp. 67 - 70, http://dx.doi.org/10.1016/j.drugalcdep.2017.03.023
,2017, 'Tobacco harm reduction with vaporised nicotine (THRiVe): The study protocol of an uncontrolled feasibility study of novel nicotine replacement products among people living with HIV who smoke', International Journal of Environmental Research and Public Health, 14, http://dx.doi.org/10.3390/ijerph14070799
,2017, 'Body composition substudy of the SECOND-LINE study – Author's reply', The Lancet HIV, 4, pp. e240, http://dx.doi.org/10.1016/S2352-3018(17)30093-0
,2017, 'Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration', EBioMedicine, 18, pp. 225 - 235, http://dx.doi.org/10.1016/j.ebiom.2017.03.024
,2017, 'HIV care in Yangon, Myanmar; successes, challenges and implications for policy', AIDS Research and Therapy, 14, pp. 10, http://dx.doi.org/10.1186/s12981-017-0137-z
,2017, 'Treatment efficacy of azithromycin 1 g single dose versus doxycycline 100 mg twice daily for 7 days for the treatment of rectal chlamydia among men who have sex with men - a double-blind randomised controlled trial protocol', BMC Infectious Diseases, 17, pp. 35, http://dx.doi.org/10.1186/s12879-016-2125-7
,2017, 'Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study', The Lancet HIV, 4, pp. e13 - e20, http://dx.doi.org/10.1016/S2352-3018(16)30189-8
,2017, 'CD4:CD8 ratio comparison between cohorts of HIV-positive Asians and Caucasians upon commencement of antiretroviral therapy', Antiviral Therapy, 22, pp. 659 - 668, http://dx.doi.org/10.3851/IMP3155
,2017, 'Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine HIV pre-exposure prophylaxis: clinical guidelines', Journal of Virus Eradication, 3, pp. 168 - 184, http://dx.doi.org/10.1016/s2055-6640(20)30338-1
,2016, 'Sexual transmission of HIV and the law: An Australian medical consensus statement', Medical Journal of Australia, 205, pp. 409 - 412, http://dx.doi.org/10.5694/mja16.00934
,2016, 'CD4+ T follicular helper and IgA+ B cell numbers in gut biopsies from HIV-infected subjects on antiretroviral therapy are similar to HIV-uninfected individuals', Frontiers in Immunology, 7, pp. 438, http://dx.doi.org/10.3389/fimmu.2016.00438
,2016, 'Antiretroviral resistance after first-line antiretroviral therapy failure in diverse HIV-1 subtypes in the SECOND-LINE study', AIDS Research and Human Retroviruses, 32, pp. 841 - 850, http://dx.doi.org/10.1089/aid.2015.0331
,2016, 'Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis', The Lancet HIV, 3, pp. e351 - e360, http://dx.doi.org/10.1016/S2352-3018(16)30015-7
,2016, 'Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART', Journal of Antimicrobial Chemotherapy, 71, pp. 1056 - 1062, http://dx.doi.org/10.1093/jac/dkv427
,2016, 'Tenofovir alafenamide: safer, but questions remain', The Lancet HIV, 3, pp. e148 - e149, http://dx.doi.org/10.1016/S2352-3018(16)00039-4
,2016, 'Reviewer acknowledgement.', AIDS Res Ther, 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8
,2016, 'Novel antiretroviral agents and universal access to HIV care', The Lancet HIV, 3, pp. e2 - e3, http://dx.doi.org/10.1016/S2352-3018(15)00244-1
,2016, 'Which HIV patients should be screened for osteoporosis: An international perspective', Current Opinion in HIV and AIDS, 11, pp. 268 - 276, http://dx.doi.org/10.1097/COH.0000000000000269
,2016, 'Reviewer acknowledgement.', AIDS Res Ther, 13, pp. 13, http://dx.doi.org/10.1186/s12981-016-0097-8
,2015, 'Erratum: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (PLoS ONE (2015)10:2 (e0118228) Doi: 10.1371/journal.pone.0118228 ))', PLoS ONE, 10, pp. e0140623, http://dx.doi.org/10.1371/journal.pone.0140623
,2015, 'The LATTE study: A provocative brew', The Lancet Infectious Diseases, 15, pp. 1116 - 1117, http://dx.doi.org/10.1016/S1473-3099(15)00224-8
,2015, 'Antiretroviral treatment use, co-morbidities and clinical outcomes among Aboriginal participants in the Australian HIV Observational Database (AHOD)', BMC Infectious Diseases, 15, pp. 326, http://dx.doi.org/10.1186/s12879-015-1051-4
,2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5
,2015, 'Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis', EBioMedicine, 2, pp. 706 - 712, http://dx.doi.org/10.1016/j.ebiom.2015.05.012
,2015, 'HIV and aging: Insights from the Asia Pacific HIV Observational Database (APHOD)', HIV Medicine, 16, pp. 152 - 160, http://dx.doi.org/10.1111/hiv.12188
,2015, 'Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: A randomised open label study for the treatment of HIV-1 infection', PLoS ONE, 10, pp. e0118228, http://dx.doi.org/10.1371/journal.pone.0118228
,